Literature DB >> 711853

Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill.

K S Chung, D A Madar, J C Goldsmith, H S Kingdon, H R Roberts.   

Abstract

Human Factor IX (Christmas factor) was isolated from the plasma of a patient with mild hemophilia B. The patient's plasma contained 5% Factor IX clotting activity but 100% Factor IX antigenic activity as determined by immunological assays, which included inhibitor neutralization and a radioimmunoassay for Factor IX. This abnormal Factor IX is called Factor IX Chapel Hill (Factor IXCH). Both normal Factor IX and Factor IXCH have tyrosine as the NH2-terminal amino acid. The two proteins have a similar molecular weight, a similar amino acid analysis, the same number of gamma-carboxyglutamic acid residues (10 gamma-carboxyglutamic acid residues), and a similar carbohydrate content. Both exist as a single-chain glycoprotein in plasma. The major difference between normal Factor IX and Factor IXCH is that the latter exhibits delayed activation to Factor IXa in the presence of Factor XIa and Ca2+. Thus, Factor IXCH differs from other previously described abnormal Factor IX molecules.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 711853      PMCID: PMC371868          DOI: 10.1172/JCI109213

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  The thiobarbituric acid assay of sialic acids.

Authors:  L WARREN
Journal:  J Biol Chem       Date:  1959-08       Impact factor: 5.157

2.  THE REACTION BETWEEN ACTIVATED PLASMA THROMBOPLASTIN ANTECEDENT AND DIISOPROPYLPHOSPHOFLUORIDATE.

Authors:  H S KINGDON; E W DAVIE; O D RATNOFF
Journal:  Biochemistry       Date:  1964-02       Impact factor: 3.162

3.  Assay of plasma thromboplastin antecedent (PTA) with artificially depleted normal plasma.

Authors:  H I HOROWITZ; W P WILCOX; M M FUJIMOTO
Journal:  Blood       Date:  1963-07       Impact factor: 22.113

4.  A study of the carrier state for plasma thromboplastin component (PTC, Christmas factor) deficiency, utilizing a new assay procedure.

Authors:  E M BARROW; W R BULLOCK; J B GRAHAM
Journal:  J Lab Clin Med       Date:  1960-06

5.  Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called stable factor (SPCA, proconvertin, factor VII) deficiency.

Authors:  C HOUGIE; E M BARROW; J B GRAHAM
Journal:  J Clin Invest       Date:  1957-03       Impact factor: 14.808

6.  Determination of hexosamines.

Authors:  S GARDELL
Journal:  Methods Biochem Anal       Date:  1958

7.  Investigation of a haemorrhagic disease due to beta-prothromboplastin deficiency complicated by a specific inhibitor of thromboplastin formation.

Authors:  P FANTL; A G MARR; R J SAWERS
Journal:  Australas Ann Med       Date:  1956-08

8.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.

Authors:  R D LANGDELL; R H WAGNER; K M BRINKHOUS
Journal:  J Lab Clin Med       Date:  1953-04

9.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

10.  Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.

Authors:  A R Thompson
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  8 in total

1.  Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.

Authors:  H A Liebman; S A Limentani; B C Furie; B Furie
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

2.  Mini-review on "A novel one-step purification of mouse factor IX".

Authors:  Sumita Choudhury; William E Plautz; Cosette Zacarias; Rinku Majumder
Journal:  J Rare Dis Res Treat       Date:  2016

3.  Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.

Authors:  K M Braunstein; C M Noyes; M J Griffith; R L Lundblad; H R Roberts
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

4.  Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.

Authors:  C M Noyes; M J Griffith; H R Roberts; R L Lundblad
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

5.  Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.

Authors:  M J Griffith; L Breitkreutz; H Trapp; E Briet; C M Noyes; R L Lundblad; H R Roberts
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

6.  Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.

Authors:  P Usharani; B J Warn-Cramer; C K Kasper; S P Bajaj
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

7.  Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.

Authors:  H E Fuchs; H G Trapp; M J Griffith; H R Roberts; S V Pizzo
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

8.  A candidate activation pathway for coagulation factor VII.

Authors:  Tina M Misenheimer; Kraig T Kumfer; Barbara E Bates; Emily R Nettesheim; Bradford S Schwartz
Journal:  Biochem J       Date:  2019-10-15       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.